| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 55 | 2025 | 956 | 7.630 |
Why?
|
| Social Support | 20 | 2024 | 204 | 4.850 |
Why?
|
| Postmenopause | 24 | 2024 | 243 | 3.250 |
Why?
|
| Social Networking | 9 | 2023 | 20 | 2.760 |
Why?
|
| Women's Health | 26 | 2023 | 199 | 2.550 |
Why?
|
| Obesity | 23 | 2022 | 841 | 2.120 |
Why?
|
| Colorectal Neoplasms | 12 | 2021 | 616 | 2.070 |
Why?
|
| Female | 109 | 2025 | 12729 | 2.040 |
Why?
|
| Middle Aged | 86 | 2025 | 7976 | 1.930 |
Why?
|
| Body Mass Index | 25 | 2022 | 970 | 1.930 |
Why?
|
| Humans | 117 | 2025 | 17707 | 1.930 |
Why?
|
| Aged | 73 | 2025 | 6150 | 1.760 |
Why?
|
| Risk Factors | 49 | 2023 | 3367 | 1.640 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2016 | 247 | 1.440 |
Why?
|
| Life Style | 6 | 2020 | 332 | 1.380 |
Why?
|
| Proportional Hazards Models | 27 | 2022 | 710 | 1.340 |
Why?
|
| Neoplasms | 6 | 2022 | 442 | 1.240 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2024 | 531 | 1.240 |
Why?
|
| Telomere | 6 | 2019 | 19 | 1.210 |
Why?
|
| Stress, Psychological | 9 | 2024 | 140 | 1.180 |
Why?
|
| Social Isolation | 4 | 2022 | 16 | 1.140 |
Why?
|
| Time-to-Treatment | 2 | 2024 | 19 | 1.080 |
Why?
|
| Neoplasm Staging | 15 | 2024 | 331 | 1.070 |
Why?
|
| Adult | 48 | 2025 | 7658 | 1.070 |
Why?
|
| Diet | 7 | 2022 | 367 | 1.060 |
Why?
|
| Dietary Fats | 6 | 2013 | 91 | 1.050 |
Why?
|
| Prognosis | 22 | 2020 | 613 | 1.050 |
Why?
|
| Body Weight | 7 | 2021 | 226 | 1.030 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 53 | 0.940 |
Why?
|
| Estrogens | 3 | 2013 | 61 | 0.920 |
Why?
|
| Feeding Behavior | 3 | 2014 | 166 | 0.880 |
Why?
|
| Quality of Life | 8 | 2016 | 521 | 0.870 |
Why?
|
| Dairy Products | 3 | 2013 | 22 | 0.870 |
Why?
|
| Prospective Studies | 28 | 2023 | 1287 | 0.860 |
Why?
|
| Coronary Artery Disease | 4 | 2016 | 133 | 0.860 |
Why?
|
| Body Size | 2 | 2020 | 31 | 0.810 |
Why?
|
| Cohort Studies | 27 | 2025 | 2589 | 0.800 |
Why?
|
| Colonic Neoplasms | 3 | 2020 | 158 | 0.800 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 47 | 0.800 |
Why?
|
| Cardiovascular Diseases | 9 | 2024 | 596 | 0.760 |
Why?
|
| Asian Americans | 2 | 2020 | 175 | 0.730 |
Why?
|
| Incidence | 17 | 2022 | 1269 | 0.720 |
Why?
|
| Public Health | 1 | 2020 | 81 | 0.650 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 75 | 0.650 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 1218 | 0.640 |
Why?
|
| Models, Theoretical | 2 | 2019 | 68 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2020 | 755 | 0.620 |
Why?
|
| Mortality | 5 | 2019 | 118 | 0.610 |
Why?
|
| Survivors | 5 | 2016 | 158 | 0.600 |
Why?
|
| Models, Statistical | 4 | 2017 | 177 | 0.600 |
Why?
|
| Survival Analysis | 13 | 2017 | 216 | 0.580 |
Why?
|
| United States | 23 | 2022 | 3914 | 0.580 |
Why?
|
| Multivariate Analysis | 10 | 2020 | 561 | 0.570 |
Why?
|
| California | 13 | 2024 | 2327 | 0.560 |
Why?
|
| Weight Loss | 4 | 2016 | 305 | 0.560 |
Why?
|
| Heart Failure | 3 | 2022 | 398 | 0.560 |
Why?
|
| European Continental Ancestry Group | 7 | 2019 | 523 | 0.540 |
Why?
|
| African Americans | 5 | 2019 | 465 | 0.530 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2025 | 74 | 0.530 |
Why?
|
| Aged, 80 and over | 14 | 2022 | 1927 | 0.500 |
Why?
|
| Medical Records | 1 | 2015 | 97 | 0.490 |
Why?
|
| Medication Adherence | 1 | 2018 | 245 | 0.480 |
Why?
|
| Weight Gain | 5 | 2016 | 175 | 0.480 |
Why?
|
| Muscle, Skeletal | 3 | 2020 | 34 | 0.470 |
Why?
|
| Telomerase | 2 | 2011 | 4 | 0.470 |
Why?
|
| Algorithms | 1 | 2015 | 237 | 0.440 |
Why?
|
| Surveys and Questionnaires | 11 | 2023 | 1322 | 0.440 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 34 | 0.440 |
Why?
|
| Biomarkers | 6 | 2018 | 312 | 0.430 |
Why?
|
| Nurses | 4 | 2009 | 35 | 0.430 |
Why?
|
| Leukocytes | 2 | 2015 | 10 | 0.410 |
Why?
|
| Telomere Shortening | 2 | 2013 | 3 | 0.410 |
Why?
|
| Coronary Disease | 6 | 2020 | 180 | 0.410 |
Why?
|
| Caregivers | 3 | 2014 | 128 | 0.400 |
Why?
|
| Diet, Reducing | 1 | 2012 | 25 | 0.400 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 17 | 0.400 |
Why?
|
| Work Schedule Tolerance | 3 | 2006 | 7 | 0.400 |
Why?
|
| Hot Flashes | 1 | 2012 | 39 | 0.400 |
Why?
|
| Affect | 1 | 2012 | 25 | 0.390 |
Why?
|
| Calcinosis | 1 | 2012 | 40 | 0.390 |
Why?
|
| Risk Assessment | 11 | 2020 | 1106 | 0.390 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2022 | 2 | 0.390 |
Why?
|
| Young Adult | 11 | 2024 | 2450 | 0.380 |
Why?
|
| Body Composition | 4 | 2021 | 90 | 0.380 |
Why?
|
| Odds Ratio | 7 | 2015 | 670 | 0.380 |
Why?
|
| Vascular Calcification | 1 | 2011 | 9 | 0.380 |
Why?
|
| Exercise | 7 | 2022 | 496 | 0.380 |
Why?
|
| Adrenal Cortex | 1 | 2011 | 1 | 0.380 |
Why?
|
| Mouth Mucosa | 1 | 2011 | 2 | 0.380 |
Why?
|
| Autonomic Nervous System | 1 | 2011 | 3 | 0.380 |
Why?
|
| Ethnic Groups | 2 | 2015 | 474 | 0.380 |
Why?
|
| Male | 17 | 2021 | 10094 | 0.370 |
Why?
|
| Biomarkers, Tumor | 3 | 2018 | 144 | 0.360 |
Why?
|
| Socioeconomic Factors | 6 | 2019 | 626 | 0.360 |
Why?
|
| Cause of Death | 5 | 2024 | 181 | 0.340 |
Why?
|
| Health Behavior | 3 | 2020 | 360 | 0.340 |
Why?
|
| Receptors, Progesterone | 4 | 2020 | 50 | 0.340 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 1322 | 0.330 |
Why?
|
| Health Status Indicators | 3 | 2009 | 63 | 0.330 |
Why?
|
| Occupational Health | 2 | 2006 | 17 | 0.330 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 448 | 0.330 |
Why?
|
| Adiposity | 3 | 2020 | 66 | 0.330 |
Why?
|
| Interpersonal Relations | 2 | 2020 | 42 | 0.320 |
Why?
|
| Sarcopenia | 2 | 2020 | 11 | 0.320 |
Why?
|
| Metabolic Syndrome | 2 | 2022 | 81 | 0.310 |
Why?
|
| Inflammation | 3 | 2022 | 64 | 0.310 |
Why?
|
| Social Class | 2 | 2017 | 121 | 0.300 |
Why?
|
| Longitudinal Studies | 8 | 2016 | 717 | 0.300 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2008 | 38 | 0.300 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2006 | 27 | 0.290 |
Why?
|
| Disease | 1 | 2007 | 3 | 0.290 |
Why?
|
| Logistic Models | 9 | 2017 | 918 | 0.290 |
Why?
|
| Sleep | 2 | 2019 | 58 | 0.280 |
Why?
|
| Adolescent | 8 | 2016 | 3671 | 0.280 |
Why?
|
| Depression | 3 | 2013 | 504 | 0.270 |
Why?
|
| Comorbidity | 5 | 2025 | 590 | 0.260 |
Why?
|
| Occupational Exposure | 1 | 2006 | 67 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 51 | 0.260 |
Why?
|
| Cancer Survivors | 2 | 2018 | 91 | 0.260 |
Why?
|
| Electronic Health Records | 4 | 2025 | 694 | 0.250 |
Why?
|
| Health Status | 1 | 2007 | 299 | 0.240 |
Why?
|
| Aging | 4 | 2014 | 163 | 0.240 |
Why?
|
| Linear Models | 5 | 2019 | 229 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 211 | 0.230 |
Why?
|
| Mastectomy | 1 | 2024 | 36 | 0.230 |
Why?
|
| Retrospective Studies | 8 | 2021 | 2471 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 13 | 0.230 |
Why?
|
| Disease Progression | 3 | 2013 | 266 | 0.230 |
Why?
|
| Adenoma | 1 | 2005 | 94 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 327 | 0.220 |
Why?
|
| Blood Glucose | 2 | 2012 | 348 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 129 | 0.220 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 146 | 0.220 |
Why?
|
| Life Change Events | 3 | 2024 | 31 | 0.210 |
Why?
|
| Registries | 5 | 2020 | 470 | 0.210 |
Why?
|
| Mammography | 1 | 2024 | 168 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 381 | 0.210 |
Why?
|
| Intra-Abdominal Fat | 2 | 2020 | 14 | 0.210 |
Why?
|
| C-Reactive Protein | 3 | 2018 | 59 | 0.210 |
Why?
|
| Colectomy | 2 | 2020 | 31 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 75 | 0.210 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 271 | 0.210 |
Why?
|
| Age Factors | 7 | 2019 | 918 | 0.200 |
Why?
|
| Time Factors | 6 | 2016 | 1095 | 0.200 |
Why?
|
| Survival Rate | 6 | 2020 | 262 | 0.200 |
Why?
|
| Smoking | 4 | 2012 | 483 | 0.200 |
Why?
|
| Models, Structural | 1 | 2012 | 2 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 314 | 0.200 |
Why?
|
| Loneliness | 1 | 2022 | 5 | 0.190 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 50 | 0.190 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 102 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2012 | 94 | 0.190 |
Why?
|
| Receptors, Estrogen | 2 | 2020 | 51 | 0.190 |
Why?
|
| Dementia | 1 | 2023 | 112 | 0.180 |
Why?
|
| Population Surveillance | 3 | 2016 | 265 | 0.170 |
Why?
|
| Causality | 2 | 2019 | 39 | 0.170 |
Why?
|
| China | 3 | 2016 | 132 | 0.170 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2020 | 4 | 0.170 |
Why?
|
| Alcohol Drinking | 1 | 2003 | 361 | 0.170 |
Why?
|
| Confounding Factors (Epidemiology) | 3 | 2013 | 86 | 0.160 |
Why?
|
| Health Status Disparities | 3 | 2021 | 147 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 397 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 513 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 4 | 2024 | 47 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 377 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2020 | 1254 | 0.150 |
Why?
|
| African Continental Ancestry Group | 2 | 2012 | 162 | 0.150 |
Why?
|
| Insulin Resistance | 2 | 2017 | 137 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2018 | 21 | 0.150 |
Why?
|
| Bias | 1 | 2018 | 103 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 25 | 0.150 |
Why?
|
| Self Report | 3 | 2019 | 252 | 0.150 |
Why?
|
| Survivorship | 1 | 2018 | 10 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 42 | 0.150 |
Why?
|
| Vegetables | 3 | 2015 | 87 | 0.150 |
Why?
|
| Pessimism | 1 | 2017 | 1 | 0.140 |
Why?
|
| Optimism | 1 | 2017 | 2 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 3 | 0.140 |
Why?
|
| Hostility | 1 | 2017 | 7 | 0.140 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 64 | 0.140 |
Why?
|
| Marriage | 1 | 2017 | 5 | 0.140 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 80 | 0.140 |
Why?
|
| Overweight | 2 | 2016 | 270 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 136 | 0.140 |
Why?
|
| Hospitalization | 2 | 2022 | 805 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2015 | 1117 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 28 | 0.130 |
Why?
|
| Child | 3 | 2022 | 2481 | 0.130 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2018 | 227 | 0.130 |
Why?
|
| Analysis of Variance | 2 | 2017 | 159 | 0.130 |
Why?
|
| Metabolic Equivalent | 1 | 2016 | 8 | 0.130 |
Why?
|
| Reproduction | 1 | 2016 | 13 | 0.130 |
Why?
|
| Pregnancy Rate | 1 | 2016 | 6 | 0.130 |
Why?
|
| Recurrence | 2 | 2014 | 189 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 5 | 0.130 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 154 | 0.130 |
Why?
|
| Longevity | 2 | 2022 | 13 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 37 | 0.130 |
Why?
|
| Marital Status | 2 | 2013 | 20 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 60 | 0.120 |
Why?
|
| Mexican Americans | 1 | 2015 | 45 | 0.120 |
Why?
|
| Thinness | 2 | 2014 | 32 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 50 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2011 | 1417 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 304 | 0.120 |
Why?
|
| Edible Grain | 2 | 2012 | 14 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2017 | 248 | 0.120 |
Why?
|
| Fruit | 2 | 2012 | 79 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 128 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 41 | 0.110 |
Why?
|
| Stillbirth | 1 | 2014 | 29 | 0.110 |
Why?
|
| Utah | 1 | 2014 | 33 | 0.110 |
Why?
|
| Cognition Disorders | 2 | 2013 | 30 | 0.110 |
Why?
|
| Abortion, Spontaneous | 1 | 2014 | 47 | 0.110 |
Why?
|
| Testicular Neoplasms | 1 | 2013 | 11 | 0.110 |
Why?
|
| Social Environment | 2 | 2020 | 87 | 0.110 |
Why?
|
| Mobility Limitation | 1 | 2014 | 16 | 0.110 |
Why?
|
| Fluoxetine | 1 | 2013 | 26 | 0.110 |
Why?
|
| Paroxetine | 1 | 2013 | 23 | 0.110 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2013 | 28 | 0.110 |
Why?
|
| Prevalence | 2 | 2017 | 882 | 0.110 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2013 | 71 | 0.110 |
Why?
|
| Breast Feeding | 1 | 2015 | 137 | 0.110 |
Why?
|
| Cellular Senescence | 1 | 2013 | 2 | 0.100 |
Why?
|
| Apolipoprotein E4 | 1 | 2013 | 2 | 0.100 |
Why?
|
| Heterozygote | 1 | 2013 | 26 | 0.100 |
Why?
|
| Patient Compliance | 2 | 2014 | 299 | 0.100 |
Why?
|
| Self Concept | 1 | 2013 | 39 | 0.100 |
Why?
|
| Sex Factors | 3 | 2020 | 639 | 0.100 |
Why?
|
| Guideline Adherence | 3 | 2024 | 155 | 0.100 |
Why?
|
| Sweating | 1 | 2012 | 9 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 80 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 115 | 0.100 |
Why?
|
| Psychology | 2 | 2014 | 16 | 0.100 |
Why?
|
| Family Characteristics | 1 | 2012 | 56 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2013 | 59 | 0.100 |
Why?
|
| Radiography | 1 | 2012 | 39 | 0.100 |
Why?
|
| Religion | 1 | 2012 | 14 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2011 | 7 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2012 | 189 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2011 | 19 | 0.100 |
Why?
|
| Selection Bias | 2 | 2019 | 18 | 0.090 |
Why?
|
| Arrhythmia, Sinus | 1 | 2011 | 2 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 58 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 12 | 0.090 |
Why?
|
| Saliva | 1 | 2011 | 12 | 0.090 |
Why?
|
| Hydrocortisone | 1 | 2011 | 18 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2012 | 53 | 0.090 |
Why?
|
| Heart Rate | 1 | 2011 | 41 | 0.090 |
Why?
|
| Health Surveys | 2 | 2018 | 260 | 0.090 |
Why?
|
| Family | 1 | 2012 | 109 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2014 | 416 | 0.090 |
Why?
|
| Regression Analysis | 3 | 2011 | 296 | 0.090 |
Why?
|
| Anxiety | 1 | 2011 | 152 | 0.090 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 2 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 4 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 8 | 0.080 |
Why?
|
| DNA | 1 | 2009 | 22 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2009 | 35 | 0.080 |
Why?
|
| Waist Circumference | 2 | 2022 | 39 | 0.080 |
Why?
|
| SEER Program | 2 | 2020 | 92 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 85 | 0.070 |
Why?
|
| Stroke | 3 | 2016 | 316 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 123 | 0.070 |
Why?
|
| Psychosocial Deprivation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Dietary Fiber | 2 | 2015 | 59 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2008 | 159 | 0.070 |
Why?
|
| Child Development | 1 | 2007 | 53 | 0.070 |
Why?
|
| Insulin | 2 | 2015 | 213 | 0.070 |
Why?
|
| Risk | 3 | 2017 | 517 | 0.070 |
Why?
|
| Melatonin | 1 | 2006 | 4 | 0.060 |
Why?
|
| Reproductive History | 1 | 2006 | 17 | 0.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2006 | 41 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2006 | 46 | 0.060 |
Why?
|
| Community Networks | 1 | 2006 | 23 | 0.060 |
Why?
|
| Meat | 1 | 2005 | 27 | 0.060 |
Why?
|
| Aircraft | 1 | 2005 | 3 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2016 | 237 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2005 | 41 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2017 | 311 | 0.060 |
Why?
|
| Income | 2 | 2017 | 88 | 0.060 |
Why?
|
| Nursing | 1 | 2004 | 2 | 0.060 |
Why?
|
| Chicago | 1 | 2024 | 25 | 0.060 |
Why?
|
| Educational Status | 2 | 2017 | 198 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2024 | 15 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2024 | 43 | 0.060 |
Why?
|
| Self Efficacy | 1 | 2004 | 68 | 0.050 |
Why?
|
| C-Peptide | 1 | 2003 | 6 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 25 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2005 | 253 | 0.050 |
Why?
|
| Temperance | 1 | 2003 | 24 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 212 | 0.050 |
Why?
|
| Metformin | 1 | 2013 | 58 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 66 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2022 | 23 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 154 | 0.050 |
Why?
|
| Research Design | 1 | 2024 | 372 | 0.050 |
Why?
|
| Albuminuria | 1 | 2012 | 38 | 0.050 |
Why?
|
| Cognition | 1 | 2022 | 82 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2012 | 81 | 0.050 |
Why?
|
| Narration | 1 | 2021 | 7 | 0.050 |
Why?
|
| Hypertension | 1 | 2005 | 498 | 0.050 |
Why?
|
| Emotions | 1 | 2021 | 35 | 0.050 |
Why?
|
| Glycated Hemoglobin A | 1 | 2012 | 215 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 19 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 59 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 2020 | 35 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 182 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 257 | 0.040 |
Why?
|
| Pregnancy | 2 | 2016 | 1535 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 1999 | 7 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2019 | 88 | 0.040 |
Why?
|
| Health Communication | 1 | 2019 | 16 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 111 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2020 | 164 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 215 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 78 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2018 | 64 | 0.040 |
Why?
|
| Body Height | 1 | 2018 | 62 | 0.040 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2018 | 2 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 161 | 0.040 |
Why?
|
| Occupations | 1 | 2017 | 16 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 3 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 5 | 0.040 |
Why?
|
| Organ Size | 1 | 2017 | 16 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 49 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2017 | 11 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2017 | 26 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 100 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 234 | 0.030 |
Why?
|
| Fast Foods | 1 | 2017 | 12 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 57 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 151 | 0.030 |
Why?
|
| Snoring | 1 | 2016 | 1 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 32 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2016 | 20 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 32 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2016 | 31 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 19 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2015 | 20 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 27 | 0.030 |
Why?
|
| Diet Records | 1 | 2015 | 36 | 0.030 |
Why?
|
| Culture | 1 | 2015 | 26 | 0.030 |
Why?
|
| Food | 1 | 2015 | 31 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Gait | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hand Strength | 1 | 2014 | 10 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 45 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 21 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 355 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 27 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 11 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 49 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2014 | 72 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 22 | 0.030 |
Why?
|
| Alleles | 1 | 2013 | 85 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 41 | 0.030 |
Why?
|
| Genotype | 1 | 2013 | 227 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 46 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2014 | 301 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2005 | 300 | 0.020 |
Why?
|
| Hispanic Americans | 1 | 2013 | 397 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 203 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2010 | 99 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 120 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 5 | 0.020 |
Why?
|
| Motor Activity | 1 | 2011 | 212 | 0.020 |
Why?
|
| Menopause | 1 | 2006 | 70 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 196 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 260 | 0.010 |
Why?
|
| Digitalis Glycosides | 1 | 1999 | 1 | 0.010 |
Why?
|
| Forms and Records Control | 1 | 1999 | 7 | 0.010 |
Why?
|
| Shock, Cardiogenic | 1 | 1999 | 6 | 0.010 |
Why?
|
| Death Certificates | 1 | 1999 | 19 | 0.010 |
Why?
|
| Minnesota | 1 | 1999 | 51 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 1999 | 20 | 0.010 |
Why?
|
| Lipids | 1 | 1999 | 82 | 0.010 |
Why?
|
| Data Collection | 1 | 1999 | 252 | 0.010 |
Why?
|
| Patient Discharge | 1 | 1999 | 153 | 0.010 |
Why?
|